

Response
2 The Department may, at its discretion, publish part or all of the information provided in your submission on the Department's website or in related documents. If information from your submission is published, the Department may identify you and/or your organisation as the author of the submission. All personal contact details will be removed prior to publishing. Yes, I consent to my identified submission being published
3 What is your name? Andrew Bowskill
7 Please select the type of individual(s) or organisation(s) you represent. Please select all that apply. - Selected Choice Other [please specify]
7.22 Please select the type of individual(s) or organisation(s) you represent. Please select all that apply. - Other [please specify] - Text Not-for-profit
8.1 What is the name of your organisation? - My organisation is called: - Text MTPConnect / Australian AMR Network
9 Are you making feedback on behalf of your organisation? Your organisation
13 Please select which chapter/s you would like to provide feedback on. You may provide feedback on as many or few chapters as you wish. 4. Health technology funding and purchasing approaches and managing uncertainty, 5. Futureproofing Australia's systems and processes
17 Please select the topics within the chapter(s) you would like to provide feedback on. 4. Health Technology funding and purchasing mechanisms and decisions 4.2. Approaches to incentivise development of products that address antimicrobial resistance (AMR)
18 Please select the topics within the chapter(s) you would like to provide feedback on. 5. Futureproofing our systems and processes 5.1. Proactively addressing areas of unmet clinical need and gaps in the PBS
114 Taking all Options within this section: 4.2. Approaches to incentivise development of products that address antimicrobial resistance (AMR) into account. Overall, to what extent could the options (if implemented) address the issues that relate to them? Address some but not most of the issue(s)
116.1 If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - HTA Fee exemptions for products that address AMR Neutral
116.2 If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - HTA Policy and Guidance changes for products that address AMR Neutral
116.3 If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Funding and reimbursement-related changes to support availability of antimicrobials Neutral